Dr. Daskivich on the Future Landscape of Prostate Cancer

Video

In Partnership With:

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.

Daskivich’s hope is that active surveillance will be the primary therapy for very low-risk and the majority of low-risk prostate cancers. For select low-risk prostate cancers, high-intensity focused ultrasound (HIFU) or other minimally invasive and minimally morbid treatments will be used for those patients who need treatment, states Daskivich. Currently, HIFU is only approved in the United States for prostate tissue ablation, but it has demonstrated efficacy as a treatment for patients with prostate cancer. HIFU should be used sparingly, as to avoid overtreatment in patients with very low-risk tumors.

For favorable-risk, low-volume, localized, intermediate-risk tumors, HIFU will become the standard of care, predicts Daskivich. For unfavorable, intermediate-risk and higher tumors, the evidence suggests that, currently, surgery and radiation are the appropriate therapies. Time will tell, concludes Daskivich.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD